{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:32:57Z","timestamp":1788993177955,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019298","name":"Greenwich Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019887","name":"GW Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.yebeh.2019.04.044","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T21:05:53Z","timestamp":1560805553000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy"],"prefix":"10.1016","volume":"97","author":[{"given":"Roy C.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler E.","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve B.","family":"Ampah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Martina","family":"Bebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy P.","family":"Szaflarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5\u20136","key":"10.1016\/j.yebeh.2019.04.044_bb0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07352689.2016.1265360","article-title":"Medicinal uses of marijuana and cannabinoids","volume":"35","author":"Grotenhermen","year":"2016","journal-title":"J Crit Rev Plant Sci"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistent epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2017-317168","article-title":"Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence","volume":"89","author":"Stockings","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"21","key":"10.1016\/j.yebeh.2019.04.044_bb0030","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistent seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.yebeh.2019.04.044_bb0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment -resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2019.04.044_bb0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2019.04.044_bb0045","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.04.044_bb0050","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2019.04.044_bb0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamapsychiatry.2018.0335","article-title":"Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis","volume":"75","author":"Scott","year":"2018","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"10.1016\/j.yebeh.2019.04.044_bb0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"part B","key":"10.1016\/j.yebeh.2019.04.044_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2016.11.020","article-title":"Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy","volume":"70","author":"Allendorfer","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0075","author":"Gardner"},{"issue":"10","key":"10.1016\/j.yebeh.2019.04.044_bb0080","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/jnnp.54.10.873","article-title":"The Chalfont Seizure Severity Scale","volume":"54","author":"J.S. D","year":"1991","journal-title":"Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.yebeh.2019.04.044_bb0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1017\/S1355617714000320","article-title":"The cognition battery of the NIH toolbox for assessment of neurological and behavioral function: validation in an adult sample","volume":"20","author":"Weintraub","year":"2014","journal-title":"J Int Neuropsychol Soc"},{"issue":"6","key":"10.1016\/j.yebeh.2019.04.044_bb0090","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1017\/S1355617714000241","article-title":"Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults","volume":"20","author":"Heaton","year":"2014","journal-title":"J Int Neuropsychol Soc"},{"issue":"11","key":"10.1016\/j.yebeh.2019.04.044_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11910-018-0882-y","article-title":"Cannabis for the treatment of epilepsy: an update","volume":"18","author":"Gaston","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0100","series-title":"Annual Meeting of the American Epilepsy Society; New Orleans, LA2018","article-title":"Impact of treatment with epidiolex (cannabidiol) on the cognitive functioning of pediatric patients with treatment-resistent epilepsy","author":"Bortnik","year":"2018"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1355617714000307","article-title":"Factor structure, convergent validity, and discriminant validity of the NIH Toolbox Cognitive Health Battery (NIHTB-CHB) in adults","volume":"20","author":"Mungas","year":"2014","journal-title":"J Int Neuropsychol Soc"},{"issue":"6","key":"10.1016\/j.yebeh.2019.04.044_bb0110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1017\/S1355617714000472","article-title":"NIH Toolbox Cognition Battery (CB): validation of executive function measures in adults","volume":"20","author":"Zelazo","year":"2014","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0115","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","article-title":"Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity","volume":"28","author":"Grimm","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.euroneuro.2008.04.008","article-title":"Effects of acute oral tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers","volume":"18","author":"Roser","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2019.04.044_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.yebeh.2019.04.044_bb0135","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.yebeh.2019.04.044_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.09.006","article-title":"The MATRICS initiative: developing a consensus cognitive battery for clinical trials","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr Res"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018309314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018309314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:26:40Z","timestamp":1761503200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018309314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":28,"alternative-id":["S1525505018309314"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.04.044","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}